This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Neoplasm of uncertain or unknown behaviour of middle ear and respiratory and intrathoracic organs중이·호흡기·흉곽내장기의 행동양식 불명 또는 미상의 신생물

Contents and key points
ItemDetails
A. Classification codesICD-10: D38 (Neoplasm of uncertain or unknown behavior of middle ear and respiratory and intrathoracic organs) | Special Copayment Reduction: V193 (Special Copayment Reduction for cancer: copayment 5% for 5 years from the registration date)
B. SynonymsNeoplasm of unknown behavior (respiratory system), neoplasm of uncertain behavior, borderline malignancy of respiratory tract, neoplasm of uncertain malignant potential (D38.0 larynx, D38.1 trachea, bronchus and lung, D38.2 pleura, D38.3 mediastinum, D38.4 thymus, D38.5 other respiratory organs)
C. Adult onsetMostly presents in adulthood (40s~60s) and is often found incidentally through respiratory symptoms or imaging. The clinical course varies with tumor location and size.
1. HistoryLaryngeal and bronchial carcinoids and paragangliomas have been recognized since the late 19th century, and the "uncertain behavior" category was established along with the development of the WHO classification system.
2. CausesSmoking, asbestos exposure, radiation, chronic inflammation, and genetic predisposition are the main risk factors, and the causes are multifactorial.
3. GeneticsVarious gene mutations (MEN1, RET, NF2, p53, etc.) are involved depending on the site, and both sporadic and hereditary forms exist.
4. General epidemiologyOverall a rare group of diseases; carcinoids occur at about 0.5~2 per 100,000 per year; laryngeal paragangliomas account for a small fraction of all head and neck paragangliomas.
5. PathophysiologyArises from neuroendocrine cells and neural crest-derived cells, with somatic mutations and epigenetic changes as the key mechanisms.
6. SymptomsChronic cough, dyspnea, blood-tinged sputum, hoarseness, ear fullness, and chest pain are the main symptoms, and functioning tumors are accompanied by symptoms of hormone hypersecretion.
7. SignsA mass on bronchoscopy, abnormal chest auscultation, lymphadenopathy, and conductive hearing loss (middle ear lesions) may be observed.
8. ScreeningRegular chest CT, low-dose CT lung cancer screening for smokers, audiometry, and the like are useful for early detection.
9. DiagnosisImaging (CT, MRI, PET-CT), bronchoscopic biopsy, immunohistochemistry, and molecular pathology are the key diagnostic tools.
10. TreatmentRadical resection comes first; when surgery is not possible, radiation therapy, embolization, and somatostatin analogue therapy are applied.
11. PrognosisVaries by histologic type; the 5-year survival rate of completely resected carcinoids is over 80%; small cell or high-grade tumors are poor.
12. PreventionSmoking cessation, minimizing exposure to occupational carcinogens, and regular imaging follow-up are the key prevention strategies.
13. ReferencesNeuroendocrine neoplasms of the larynx: an overview … and 9 other papers

1. History

The history of neoplasms of uncertain behavior arising in the middle ear, respiratory, and intrathoracic organs dates back to the late 19th century, when the concept of neuroendocrine tumors began to be established. In 1867, Theodor Langhans first described carcinoid-like structures in the small intestine, and in 1888 Otto Lubarsch systematically reported ileal carcinoids in autopsy cases. Later, in 1907, Siegfried Oberndorfer named this group of tumors 'Karzinoid (carcinoid)', forming the modern concept. Bronchial carcinoids were first recognized in the 1930s and were initially classified as bronchial adenocarcinomas, but later, as their neuroendocrine differentiation was characterized, they became established as an independent disease group.

Laryngeal paraganglioma is a rare subtype of head and neck paraganglioma; in 1952 Duncan and Lack published the first systematic case report. As research on head and neck chemoreceptor tumors subsequently became more active, the clinical and pathological features of laryngeal and middle ear paragangliomas were gradually elucidated. Middle ear paraganglioma (glomus tympanicum tumor) was recognized as a distinct entity through the studies of Rosenwasser (1945) and Guild (1953).

Since publishing its first classification of lung tumors in 1967, the World Health Organization (WHO) has progressively refined the "uncertain or unknown behavior" category through successive revisions in 1981, 1999, 2004, 2015, and 2021. The 2021 WHO Classification of Thoracic Tumours (5th edition) integrated molecular pathological features to further subdivide the subtypes of neuroendocrine neoplasms, and in the process the uncertainty regarding the malignant potential of some tumors was redefined. ICD-10 code D38 covers borderline tumors that are histologically neither benign nor malignant, reflecting the evolution of this classification system.

With respect to neoplasms of uncertain behavior of the thymus, the history of thymoma begins with the descriptions by Grandhomme and Laquer in the early 1900s, and in 1944 Castleman published a landmark paper distinguishing lymphoid hyperplasia of the thymus from thymoma. The classification of thymoma evolved through Müller-Hermelink (1985) and then WHO (1999, 2004, 2021), and a detailed histologic classification ranging from type A to type C (thymic carcinoma) is currently used.


2. Causes

The tumors coded under D38 differ in causative factors according to the site of origin and tissue of origin, but they commonly arise from the interaction of complex environmental, genetic, and epigenetic factors.

Smoking is a major risk factor for the development of bronchial and pulmonary neuroendocrine tumors. Atypical carcinoid has been reported to be more strongly associated with smoking than typical carcinoid, and the risk of transition to small cell lung cancer is also higher in smokers. However, typical carcinoid also occurs in nonsmokers, suggesting that mechanisms other than smoking are important.

As occupational exposures, asbestos, chromates, nickel, and radionuclides are known to increase the risk of pleural mesothelioma and pulmonary neoplasms. Asbestos exposure is particularly closely associated with pleural tumors corresponding to D38.2. Radon gas exposure has also been identified as a risk factor for pulmonary neoplasms.

Chronic inflammation and immune status also play an important role. Chronic obstructive pulmonary disease (COPD), recurrent pneumonia, and post-tuberculosis scarring can induce local dysplastic changes and promote neoplasm development. Thymic neoplasms are frequently accompanied by autoimmune diseases such as myasthenia gravis and pure red cell aplasia, suggesting that immune dysfunction is involved in pathogenesis.

As a genetic predisposition, multiple endocrine neoplasia type 1 (MEN1) is strongly associated with bronchial carcinoid. Bronchial carcinoid develops in about 5–10% of patients with MEN1, and unlike sporadic carcinoid, it tends to appear at a younger age and as multiple lesions.

In middle ear and laryngeal paragangliomas, SDHB, SDHC, and SDHD gene mutations are associated with hereditary forms, and a family history is identified in about 40%. Because paragangliomas are closely related to abnormalities of the oxygen-sensing pathway, the risk of development may increase with long-term exposure to hypoxic environments.


3. Genetics

Tumors in the D38 category show highly heterogeneous genetic abnormalities depending on the site of origin. In bronchopulmonary carcinoids, MEN1 gene (11q13) mutations are found in about 36–40% of typical carcinoids and more than 50% of atypical carcinoids. The MEN1 protein menin is a tumor suppressor that performs various nuclear functions, such as regulation of histone methylation and repression of gene transcription, and its loss of function causes unregulated proliferation of neuroendocrine cells.

Among chromosomal abnormalities, 11q loss is the most commonly observed in bronchial carcinoids, appearing rarely in typical carcinoids and frequently in atypical carcinoids. 9p loss and 3p loss have also been reported and are used as indicators reflecting a tendency toward malignant transformation. Tumor mutation burden (TMB) is low in carcinoids and high in small cell lung cancer, so the spectrum of genetic abnormalities is clearly distinguished by histologic type.

In thymic neoplasms, the p.L424H mutation of the GTF2I gene (general transcription factor II-I) is found in about 74–82% of type A and type AB thymomas; this mutation is associated with a benign clinical course, and its potential use as a prognostic factor has been proposed. In thymic carcinoma, various genetic abnormalities such as TP53, CDKN2A, KIT, EGFR are observed.

In head and neck paragangliomas (including middle ear and laryngeal), mutations in the SDH (succinate dehydrogenase) complex genes are central. Because SDHD mutations follow maternal imprinting, they show a unique inheritance pattern in which the phenotype appears only with paternal transmission. SDHB mutations are clinically important because of a high risk of malignant transformation, and SDHA, SDHC, and SDHAF2 mutations have also been reported. Because about 30–40% of all paragangliomas are hereditary, caused by germline mutations, genetic counseling and family screening are recommended at new diagnosis.

In pleural neoplasms, mutations of the BAP1 (BRCA1-associated protein 1) gene are observed not only in malignant pleural mesothelioma but also in pleural neoplasms of uncertain behavior, and loss of BAP1 function is associated with BRCA pathway abnormalities and impaired cell cycle regulation.


4. General epidemiology

The tumors included in D38 make up a group of rare diseases with an overall low incidence. The overall incidence of bronchopulmonary neuroendocrine tumors is estimated at about 0.5–2 per 100,000 population per year, of which typical carcinoid accounts for about 80–90% and atypical carcinoid for 10–20%. According to US SEER data, pulmonary carcinoids account for about 1–2% of all pulmonary neoplasms, and the incidence has shown an increasing trend over the past 30 years, mainly reflecting increased incidental detection due to advances in imaging technology.

In terms of sex distribution, typical carcinoid shows a slightly higher frequency in women, whereas atypical carcinoid shows little difference between men and women. The mean age at onset is 45–55 years for typical carcinoid and 55–65 years for atypical carcinoid, the latter occurring at an older age. By race, incidence is reported to be higher in White people and relatively lower in Black people.

Laryngeal paraganglioma is an extremely rare tumor accounting for less than about 5% of all head and neck paragangliomas and is characterized by female predominance (female:male = 3:1). It occurs mainly in people in their 40s to 60s and predominantly in the supraglottic larynx. Middle ear paraganglioma (glomus tympanicum tumor) is relatively common among head and neck paragangliomas and accounts for about 0.6% of all head and neck tumors. The worldwide incidence is about 1 per 1,000,000, also with female predominance.

Thymic neoplasms have an incidence of about 0.15 per 100,000 population per year and occur predominantly in people in their 40s to 60s. Pleural neoplasms of uncertain behavior show a high incidence among workers in asbestos-related occupations and vary greatly by country. Mediastinal neoplasms differ in histologic type depending on location: thymic tumors and germ cell tumors predominate in the anterior mediastinum, cystic lesions in the middle mediastinum, and neurogenic tumors in the posterior mediastinum.


5. Pathophysiology

The pathogenesis of D38 neoplasms is broadly divided into two axes according to tissue of origin. The first is tumors derived from the diffuse neuroendocrine system (carcinoid, paraganglioma), and the second is tumors of epithelial, mesothelial, and lymphoid origin (thymoma, pleural neoplasms).

Bronchopulmonary carcinoids originate from neuroendocrine cells of the airway mucosa (Kulchitsky cells or bronchial neuroendocrine cells). Normal neuroendocrine cells secrete serotonin, chromogranin, synaptophysin, and others, and are involved in maintaining airway homeostasis. Tumors form when loss of MEN1 gene function or abnormalities of other cell cycle regulatory genes disrupt the balance between cell proliferation and death. At the molecular level, activation of the PI3K/AKT/mTOR pathway has been confirmed to play a central role in the growth and survival of carcinoid cells.

Paragangliomas arise from paraganglion cells (glomus cells or chief cells) derived from the neural crest. These cells function as chemoreceptors that sense changes in oxygen partial pressure, and with SDH complex gene mutations, succinate accumulates excessively and stabilizes HIF-1α (hypoxia-inducible factor). As a result, angiogenic factors (such as VEGF) are overexpressed, and a so-called 'pseudohypoxic state' forms, in which persistent hypoxic response signaling drives tumor proliferation.

In thymic neoplasms, the underlying mechanism is unregulated proliferation of thymic epithelial cells. GTF2I mutations interfere with the normal differentiation of the thymic epithelium and increase cell survival signaling. As the mechanism by which myasthenia gravis accompanies thymoma, abnormal loss of immune tolerance to autoantigens (acetylcholine receptor-like epitopes) has been proposed.

In pleural neoplasms, loss of BAP1 function deregulates the activity of the polycomb repressive complex, globally altering gene expression, and chronic oxidative stress and DNA damage caused by asbestos fibers accelerate these genetic abnormalities. The Hippo signaling pathway (YAP/TAZ activation) is being shown to play a key role in the transformation of mesothelial cells.


6. Symptoms

Symptoms of D38 neoplasms vary widely depending on the site of origin and whether the tumor is functional.

About 40% of bronchopulmonary carcinoids are asymptomatic and are discovered incidentally on chest X-ray or CT. When symptoms are present, the most common are chronic cough (lasting weeks to months), blood-streaked sputum or hemoptysis, recurrent pneumonia (postobstructive pneumonia due to airway obstruction), and wheezing. Central lesions prominently cause airway obstruction symptoms, whereas peripheral lesions are often asymptomatic or present with chest pain. Functional carcinoids can cause carcinoid syndrome (facial flushing, diarrhea, abdominal pain, cardiac valvular disease), but its frequency in bronchial carcinoids is lower than in gastrointestinal carcinoids. Ectopic Cushing syndrome (ACTH secretion) occurs rarely.

The main symptoms of laryngeal paraganglioma are hoarseness, dysphagia, dyspnea, and a sensation of a mass in the neck. Functional tumors may be accompanied by hypertensive attacks, headache, sweating, and palpitations, but most are nonfunctional. In middle ear paraganglioma (glomus tympanicum tumor), pulsatile tinnitus is the most characteristic symptom, accompanied by conductive hearing loss and a sensation of ear fullness. As the lesion enlarges, facial nerve palsy and otorrhea may occur.

Thymic neoplasms are asymptomatic in about 40%, and chest pain, cough, and superior vena cava syndrome (facial edema, distended neck veins) may occur due to mediastinal compression. Paraneoplastic syndromes such as myasthenia gravis (accompanying about 30–45%), pure red cell aplasia (about 5%), and hypogammaglobulinemia (Good syndrome) are important clinical clues. In pleural neoplasms, chest pain and dyspnea due to pleural effusion are common.


7. Signs

Signs found on physical examination also vary by site and histologic type. In bronchopulmonary carcinoid, localized wheeze or decreased breath sounds may be observed on auscultation. When postobstructive pneumonia develops, dullness to percussion and increased bronchial breath sounds appear over the affected segment. In peripheral carcinoids, physical examination findings are often nonspecific or absent.

When carcinoid syndrome accompanies a functional carcinoid, facial flushing, jugular venous waveform abnormalities due to tricuspid regurgitation, and signs of right heart failure (lower extremity edema, hepatomegaly, ascites) may appear. In ectopic ACTH-secreting carcinoids, the typical signs of Cushing syndrome are observed: central obesity, moon face, buffalo hump fat accumulation at the back of the neck, skin striae, and proximal muscle weakness.

In laryngeal paraganglioma, laryngoscopy reveals a pulsatile submucosal mass in the supraglottis. Because of the tumor's hypervascularity, excessive bleeding may occur at biopsy, so caution is needed. External jugular vein distension or enlargement of perilaryngeal lymph nodes may be observed. In middle ear paraganglioma, a pulsatile red mass behind the tympanic membrane (rising sun sign) on otoscopic examination is characteristic. Facial nerve dysfunction (graded by the House-Brackmann classification) may be present.

In thymic neoplasms accompanied by myasthenia gravis, neuromuscular signs such as ptosis, diplopia, difficulty swallowing, and limb weakness are found. If superior vena cava syndrome is present, edema and venous distension of the face, neck, and upper extremities are prominent. In postobstructive adhesive pleuritis, a pleural friction rub may be heard on auscultation.


8. Screening

Because of their low incidence, no systematic population-based screening program for D38 neoplasms has been established to date. However, targeted surveillance and opportunistic screening of high-risk groups are important.

Low-dose chest CT (LDCT) is recommended annually for high-risk smokers aged 45–74 years (30 pack-years or more, currently smoking or quit within 15 years) (US USPSTF recommendation, 2021) and contributes to early detection of bronchopulmonary neoplasms. Carcinoids are also increasingly discovered incidentally in this process.

When hereditary paraganglioma is suspected (family history, multiple lesions, onset before age 40), SDH gene panel testing is performed, and in identified mutation carriers, surveillance with regular biochemical testing (plasma or 24-hour urine metanephrines and catecholamines) and whole-body MRI/functional imaging (68Ga-DOTATATE PET-CT) is recommended.

In patients with MEN1 syndrome or confirmed carriers of MEN1 gene mutations, surveillance chest CT every 3 years is recommended to screen for bronchial carcinoid. With respect to thymic neoplasms, it is standard to perform chest CT in all patients newly diagnosed with myasthenia gravis to evaluate for thymic lesions.

In patients with audiological abnormalities (pulsatile tinnitus, conductive hearing loss of unknown cause), temporal bone CT and otoscopic examination are performed to screen for middle ear paraganglioma. In particular, regular hearing tests and otolaryngologic examination are recommended for carriers of familial paraganglioma.


9. Diagnosis

The definitive diagnosis of D38 neoplasms is based on histopathological confirmation, with imaging studies and biochemical and molecular tests used as adjuncts.

In imaging diagnosis, chest CT is the first-line test to evaluate the location and size of the tumor and whether it invades surrounding structures. MRI has excellent soft tissue resolution and is useful for evaluating thymic, mediastinal, and pleural neoplasms. In particular, combined CT and MRI are essential for evaluating middle ear and laryngeal paragangliomas: CT assesses bone invasion, and MRI assesses the vascularity and soft tissue spread of the tumor. 68Ga-DOTATATE PET-CT is a highly sensitive imaging modality that replaces conventional 111In-octreotide scintigraphy for staging and surveillance of recurrence of somatostatin receptor-expressing carcinoids and paragangliomas.

Histopathology and immunohistochemistry are central to confirmation. Diagnosis of bronchopulmonary carcinoid involves identifying organoid, ribbon-like, and trabecular architectural patterns on hematoxylin-eosin staining and confirming positive expression of neuroendocrine markers such as chromogranin A, synaptophysin, and CD56 by immunohistochemistry. The Ki-67 proliferation index and mitotic count are the key criteria for classifying typical (Ki-67 <5%, mitoses <2/2mm²) versus atypical (Ki-67 5–20%, mitoses 2–10/2mm²) carcinoid. Thymic neoplasms are classified by histologic type using CK5/6, p63 (epithelial markers) and TdT, CD1a (immature T lymphocyte markers).

As biochemical tests, serum chromogranin A and plasma or urine metanephrines are used as activity markers for neuroendocrine tumors and paragangliomas. If carcinoid syndrome is suspected, 24-hour urine 5-HIAA (5-hydroxyindoleacetic acid) is measured. For molecular diagnosis, SDH and MEN1 gene mutation analysis is used to identify hereditary tumors, and analyses such as FISH for 1p19q codeletion aid in differential diagnosis.


10. Treatment

Surgical resection is the first-line treatment for D38 tumors. In bronchopulmonary carcinoid, curative lung resection (lobectomy or segmentectomy ± lymph node dissection) is the standard procedure, and for central lesions, lung preservation through bronchoplasty is attempted. Bronchoscopic endoscopic resection can be applied in a small number of selected cases in which complete resection is possible, but because the local recurrence rate is high, careful patient selection is required. In laryngeal paraganglioma, transcervical lateral laryngotomy is the standard approach, and because the tumor is hypervascular, preoperative embolization is often performed.

In middle ear paraganglioma, various surgical procedures ranging from transcanal tympanic approaches to mastoidectomy and the infracochlear approach are applied depending on the size and extent of the tumor. Preservation of the auditory nerve and the facial nerve are key goals of surgical planning. In thymic neoplasms, total thymectomy is standard, and particularly when myasthenia gravis is present, thymectomy also contributes to symptom improvement.

Radiation therapy is applied when complete resection is not possible, for residual disease after surgery, and for multiple or metastatic paragangliomas. Stereotactic body radiation therapy (SBRT) and CyberKnife are used as alternatives for middle ear and laryngeal lesions with high surgical risk. Somatostatin receptor analogs (octreotide, lanreotide) are used for tumor growth inhibition and symptom control in somatostatin receptor-positive carcinoids, and peptide receptor radionuclide therapy (PRRT, 177Lu-DOTATATE) has been shown to prolong survival in unresectable advanced carcinoids (NETTER-1 trial).

As systemic therapy, everolimus (an mTOR inhibitor) is approved for second-line treatment of advanced bronchopulmonary carcinoid (RADIANT-4 trial), and antiangiogenic agents such as sunitinib are also under investigation. Cytotoxic chemotherapy (etoposide + cisplatin) is generally of low efficacy in carcinoids and is used only in a limited manner for high-grade neuroendocrine tumors or carcinoid crisis.


11. Prognosis

The prognosis of D38 neoplasms differs greatly depending on histologic type, location, completeness of resection, and presence of distant metastasis. Typical carcinoid has a relatively favorable prognosis, with 5-year survival of 87–92% and 10-year survival of 82–87% after complete resection. Even with lymph node metastasis, 5-year survival remains above 70%. Atypical carcinoid has a poorer prognosis than the typical form, with 5-year survival of 40–70% and a median survival of around 33 months when distant metastasis occurs.

Laryngeal paraganglioma mostly has a favorable prognosis with complete resection, and malignant transformation is reported in less than about 5%. Middle ear paraganglioma also allows long-term survival after complete resection, but when skull base invasion or temporal bone destruction is present, the recurrence rate is high and surgery-related morbidity increases. The prognosis of thymic neoplasms differs by WHO histologic type: 5-year survival for types A and AB is over 90%, whereas for type B3 and thymic carcinoma (type C) it is less than 50%. The Masaoka stage of thymoma is also an important prognostic factor, with 5-year survival of over 95% for stage I and 50% or less for stage IV.

In metastatic or unresectable D38 tumors, the introduction of somatostatin analogs and PRRT has significantly improved survival. In midgut carcinoids treated with 177Lu-DOTATATE PRRT (including those of small intestinal origin, extrapolated to bronchopulmonary tumors), a marked difference in median progression-free survival was reported: 28.4 months in the treatment group versus 8.5 months in the placebo group (NETTER-1 study). The Ki-67 index, serum chromogranin A level, and loss of SDHB expression are major prognostic factors.


12. Prevention

Prevention of D38 neoplasms can be divided into minimizing exposure to causative risk factors, early detection of hereditary syndromes, and secondary prevention through regular follow-up.

The most effective measure for primary prevention is smoking cessation. Smoking is a risk factor for atypical carcinoid and other bronchopulmonary malignant neoplasms, and the risk reduction after quitting increases over time. Occupational asbestos exposure should be minimized through strict workplace safety standards (use of personal protective equipment, environmental monitoring, replacement of asbestos-containing materials), which is particularly important for preventing pleural neoplasms. Improving ventilation of living spaces to reduce radon exposure is also recommended.

For secondary prevention (early detection), participation in standardized surveillance programs is essential for patients with MEN1 syndrome and carriers of SDH gene mutations. Because MEN1-associated bronchial carcinoid can occur at a relatively young age, regular chest CT surveillance is recommended from age 10 onward. In paraganglioma carriers, surveillance with biochemical testing and whole-body imaging allows early diagnosis and treatment at the small-tumor stage. With respect to thymic neoplasms, prompt chest CT evaluation of patients with myasthenia gravis allows detection at an early stage. Because recurrence is possible even after complete resection, regular chest CT follow-up (every 6 months for the first 2 years, then once a year) is recommended.


13. References

  1. Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-233. DOI: 10.1056/NEJMoa1316158. PMID: 25014687.

  2. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135. DOI: 10.1056/NEJMoa1607427. PMID: 28076709.

  3. Travis WD, Brambilla E, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart (4th ed). IARC Press. 2015. ISBN: 978-92-832-2468-1.

  4. Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968-977. DOI: 10.1016/S0140-6736(15)00817-X. PMID: 26703889.

  5. Papathomas TG, Gaal J, Corssmit EP, et al. Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC-PGL syndromes. Eur J Endocrinol. 2014;170(1):1-12. DOI: 10.1530/EJE-13-0624. PMID: 24072737.

  6. Filosso PL, Guerrera F, Evangelista A, et al. Prognostic model of survival for typical bronchial carcinoid tumours: analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group. Eur J Cardiothorac Surg. 2015;48(3):441-447. DOI: 10.1093/ejcts/ezu495. PMID: 25564512.

  7. Bosman FT, Carneiro F, Hruban RH, Theise ND (eds). WHO Classification of Tumours of the Digestive System (4th ed). IARC Press. 2010. ISBN: 978-92-832-2410-0.

  8. Offergeld C, Brase C, Yaremchuk S, et al. Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo). 2012;67(S1):19-28. DOI: 10.6061/clinics/2012(Sup01)04. PMID: 22584701.

  9. Detterbeck FC, Parsons AM. Thymic tumors. Ann Thorac Surg. 2004;77(5):1860-1869. DOI: 10.1016/j.athoracsur.2003.10.001. PMID: 15111200.

  10. Kebebew E, Duh QY, Clark OH. Parathyroid cancer: clinical presentation, diagnosis, and treatment. Am J Surg. 1999;177(4):277-281. DOI: 10.1016/S0002-9610(99)00022-8. PMID: 10365867.